| I. Background | |
CTLA4 是一種 T 細(xì)胞共受體，也被稱為 CD152。與 CD28 相比，CTLA4 與 B7 家族分 子（包括 CD80 和 CD86）在抗原呈遞細(xì)胞（APCs）上具有更強(qiáng)的結(jié)合親和力。盡管 CTLA4 與 B7 共刺激受體結(jié)合，但它在 T 細(xì)胞的活化中起負(fù)作用。在 T 細(xì)胞受體（TCR） 識(shí)別 APC 的主要組織相容性復(fù)合體（MHC）呈遞的抗原后，T 細(xì)胞的 CD28 與 APC 的 B7 結(jié)合，通過阻斷 T 淋巴細(xì)胞反應(yīng)、減少 T 淋巴細(xì)胞增殖、抑制 Treg 淋巴細(xì)胞活性、減少細(xì) 胞因子分泌，導(dǎo)致 T 細(xì)胞活化從而抑制免疫反應(yīng)。 | |
| II. Description | |
CTLA4 IL2-Promoter Reporter Jurkat 報(bào)告基因藥靶模型很好的模擬了體內(nèi) CTLA4&IL2 的信號(hào)轉(zhuǎn)導(dǎo)過程，原理見下圖所示。 Figure 1. CTLA4 IL2-Promoter Reporter Jurkat 細(xì)胞模型原理圖 | |
| III. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | IL2 Promoter |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+10 μg/ml blasticidin+1 μg/ml puromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Homo sapiens, human |
| Tissue: | Peripheral blood |
| Disease: | Childhood T acute lymphoblastic leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| Ⅴ. Representative Data | |
Figure 1. Recombinant Jurkat stably expressing human CTLA4.
Figure 2. Dose Response of lpilimumab in CTLA4/IL2 Promoter Reporter-Jurkat Cells (C39) with TCR Activator Cell, the EC50=2.83μg/ml .
化工儀器網(wǎng)